PDS Biotech Swaps Four Directors for Three Pharma Veterans, Leaves One Seat Open
PDSB has more than doubled off its 52-week low of $0.195 on light trading volume (0.3× avg).
Summary
PDS Biotech's board turned over almost entirely on October 18, with four directors out and three pharma industry veterans in, leaving one seat vacant as the company pursues a PDS0101 partner and a PDS0301 Phase 3 trial.
Key Events · Executive and Board Changes · PDSB
-
Four Directors Resign, Three Appointed
Kamil Ali-Jackson, Stephen Glover, Gregory Freitag and Otis Brawley resigned effective October 18, 2026, and Deborah Ramsdell, John Dawson CBE and Bruce Wendel were appointed the same day. The company states none of the resignations resulted from a disagreement.
-
Board Cut to Seven, One Vacancy Open
The board fixed its size at seven directors, filling three of four vacancies — one seat remains unfilled.
-
New Directors' Deal and Regulatory Background
Dawson was CEO of Oxford Biomedica and closed deals worth over $1.75bn; Wendel led business development at Bristol-Myers Squibb and Abraxis; Ramsdell is a regulatory specialist who served on boards of four biotechs sold for $350M-$1.1B.
-
Director Option Grants
Each new director received a nonqualified option for 22,700 shares at the October 16, 2026 closing price, vesting in three annual installments of 7,566, 7,567 and 7,567 shares.
Analysis · PDSB · Life Sciences
The timing is the story here: weeks after Nant Capital's $22.55M PIPE put Dr. Patrick Soon-Shiong on the board, and with a going-concern warning and a Nasdaq bid-price deficiency hanging over the company, four directors — including the oncology expertise of Otis Brawley — resigned at once. In their place came three executives with commercialization, regulatory and deal-making backgrounds. Their stated mandate is to advance PDS0301 into a Phase 3 colorectal cancer trial and find a partner for PDS0101, which tells you the board is being rebuilt around partnership and financing work rather than clinical oversight alone. One of the four vacancies was left unfilled, and the company says none of the departures stemmed from a disagreement.
How filings like this one have moved
In the 30 days to Oct 20, 2026, 29.2% of the 1466 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PDSB was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $96.2M. The 52-week trading range was $0.20 to $1.79. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.